Evidence map›Paper›PMID 33440640›Full record

ReviewVaccines2021

SARS-CoV-2 Spike Protein Elicits Cell Signaling in Human Host Cells: Implications for Possible Consequences of COVID-19 Vaccines.

Yuichiro J Suzuki, Sergiy G Gychka

Open access · goldAbstract readReview
In one paragraph

Review in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Effects of spike proteins on angiotensin converting enzyme 2 (ACE2).Archives of biochemistry and biophysics · 2023
    Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Yuichiro J SuzukiDepartment of Pharmacology and Physiology, Georgetown University Medical Center, Washington, DC 20007, USA.ORCID 0000-0001-6689-0497
Sergiy G GychkaDepartment of Pathological Anatomy N2, Bogomolets National Medical University, 01601 Kiev, Ukraine.
Bogomolets National Medical University · UAGeorgetown University · US

Funding

New mechanism of cellular protein oxidationR21AI142649 · NIAID · GEORGETOWN UNIVERSITY · PI SUZUKI, YUICHIRO JUSTIN · 2019 to 2020
$428k
Oxidant-mediated amino acid conversions in alcohol abuseR03AA026516 · NIAAA · GEORGETOWN UNIVERSITY · PI SUZUKI, YUICHIRO JUSTIN · 2019 to 2020
$156k
Endogenous protein engineering mechanismof oxidative stress in Alzheimer's diseaseR03AG059554 · NIA · GEORGETOWN UNIVERSITY · PI SUZUKI, YUICHIRO JUSTIN · 2018 to 2019
$156k
NIAAA NIH HHS R03 AA026516NIAID NIH HHS R21 AI142649NIA NIH HHS R03 AG059554NIH HHS R21AI142649, R03AG059554, R03AA026516
6 · The paper itself

Abstract

The world is suffering from the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 uses its spike protein to enter the host cells. Vaccines that introduce the spike protein into our body to elicit virus-neutralizing antibodies are currently being developed. In this article, we note that human host cells sensitively respond to the spike protein to elicit cell signaling. Thus, it is important to be aware that the spike protein produced by the new COVID-19 vaccines may also affect the host cells. We should monitor the long-term consequences of these vaccines carefully, especially when they are administered to otherwise healthy individuals. Further investigations on the effects of the SARS-CoV-2 spike protein on human cells and appropriate experimental animal models are warranted.

Indexed as

cell signalingcoronavirusCOVID-19SARS-CoV-2spike proteinvaccine

Identifiers

PMID33440640
PMCPMC7827936
OpenAlexW3120721583

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.